Literature DB >> 32531133

COVID 19 and its impact on cosmetic dermatology.

Hassan Galadari1, Atula Gupta2, George Kroumpouzos3,4, Martin Kassir5, Lidia Rudnicka6, Torello Lotti7, Roberta Vasconcelos Berg8, Mohamad Goldust8.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32531133      PMCID: PMC7307115          DOI: 10.1111/dth.13822

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   3.858


× No keyword cloud information.
Dear Editor, The world was put on high alert when an outbreak of a novel coronavirus disease (COVID‐19) was declared a pandemic by the World Health Organization (WHO) in early March 2020. , , COVID‐19 looms as a serious medical crisis inflicting both human and economic suffering. , , Before pandemic, dermatologists, plastic surgeons, and other aesthetic practioners were all thriving amid the cosmetic boom. As COVID‐19 spreads around the globe, it has become evident that this virus has the ability to significantly derail the world economy. , The past 5 years have seen a boom in both minimally invasive and surgical cosmetic procedures. Studies suggest that social media has played a pivotal role in raising awareness about aesthetic medicine and cosmetic dermatology. Dermatologists witnessed a huge demand for facial rejuvenation procedures like platelet‐rich plasma treatment, dermal fillers, mesotherapy, microdermabrasion, and chemical peels. A plethora of laser and light devices for skin resurfacing, hair reduction, scar treatments, skin tightening, and fat reduction has dominated cosmetic dermatology practices worldwide. As the coronavirus pandemic has grown in magnitude, the safety of ablative resurfacing lasers, microneedling, and dermatological surgery procedures have become questionable. Coronavirus even though not epidermotropic, is shed as aerosols or transmitted via fomites. It is prudent that dermatologists defer elective aesthetic treatments for their patients. However, essential dermatologic procedures like Mohs surgery may be undertaken with adequate personal protective equipment (PPE). Controlling an epidemic means “flattening the epidemiologic curve.” This is done by reducing person‐to‐person contact and is called “social distancing.” When it comes to understanding COVID‐19's impact on a cosmetic dermatology practice, two aspects are worth distinguishing: practical and psychological. During lockdowns, patients are prevented from availing nonessential facilities due to movement constraints. In addition, a slowing economy and reduced discretionary spending discourages customers to undergo expensive cosmetic treatments imposing a practical restriction. A psychological barrier and a “wait‐and‐see” attitude is common for aesthetic dermatology procedures when populations are faced with a massive uncertainty of the type that COVID‐19 is presenting to the world. Pharmaceutical companies dealing with premium skin care products (many being produced in Italy, Spain, France, and United States) are suffering from trade restrictions. The manufacturing units for laser devices in Taiwan, South Korea, United States, and Israel are likely to slow production in the coming weeks, further impacting the supply chain. The bright spot in this crisis could be an accelerated shift to teledermatology. Mobile messaging and video consultations are essential in maintaining continuity in dermatological as well as aesthetic practice. Teledermatology, with all its limitations has certainly been a great strength for dermatologists and cosmetic practioners alike. The COVID 19 epidemic is the time when governments and medical communities should unify. Dermatologists and plastic surgeons even though not on the frontline, can contribute meaningfully in ways such as loaning ventilators to other facilities, donating PPE, providing hospital spaces, and if required volunteer to be deployed on the front. The bottom line still remains that finances and elective procedures such as aesthetics will always be secondary to primary health and survival during a pandemic with potentially fatal consequences such as COVID 19. Recently, some countries in Europe, for example, Switzerland, and Germany, where the number of new cases is progressively decreasing, are in the process of gradually loosening the rigid lockdown rules. In this context, medical clinics that offer elective procedures, as well as aesthetic clinics, are expected to return to work within a few days. This decision is based on the relatively low risk of transmission, since interpersonal contact occurs between a few individuals and considering the use of suitable PPE. We hope that after this acute crisis, patients might return to aesthetic procedures, possibly with a renewed passion.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.
  8 in total

1.  The effect of quarantine and isolation for COVID-19 in general population and dermatologic treatments.

Authors:  Aseem Sharma; Regina Fölster-Holst; Martin Kassir; Jacek Szepietowski; Mohammad Jafferany; Torello Lotti; Mohamad Goldust
Journal:  Dermatol Ther       Date:  2020-04-25       Impact factor: 2.851

2.  Priorities for global health community in COVID-19 pandemic.

Authors:  Lidia Rudnicka; Mrinal Gupta; Martin Kassir; Mohammad Jafferany; Torello Lotti; Roxanna Sadoughifar; Mohamad Goldust
Journal:  Dermatol Ther       Date:  2020-04-08       Impact factor: 2.851

Review 3.  Psoriatic arthritis and COVID-19 pandemic: Consequences in medical treatment?

Authors:  Uwe Wollina; Massimo Fioranelli; Mohamad Goldust; Torello Lotti
Journal:  Dermatol Ther       Date:  2020-06-30       Impact factor: 3.858

4.  Solidarity and transparency against the COVID-19 pandemic.

Authors:  Gulhima Arora; George Kroumpouzos; Martin Kassir; Mohammad Jafferany; Torello Lotti; Roxanna Sadoughifar; Zuzanna Sitkowska; Stephan Grabbe; Mohamad Goldust
Journal:  Dermatol Ther       Date:  2020-04-13       Impact factor: 2.851

5.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

6.  Epidemiological research priorities for public health control of the ongoing global novel coronavirus (2019-nCoV) outbreak.

Authors:  Benjamin J Cowling; Gabriel M Leung
Journal:  Euro Surveill       Date:  2020-02-11

7.  WHO Declares COVID-19 a Pandemic.

Authors:  Domenico Cucinotta; Maurizio Vanelli
Journal:  Acta Biomed       Date:  2020-03-19

8.  COVID-19 and economy.

Authors:  Mrinal Gupta; Ayman Abdelmaksoud; Mohammad Jafferany; Torello Lotti; Roxanna Sadoughifar; Mohamad Goldust
Journal:  Dermatol Ther       Date:  2020-04-08       Impact factor: 3.858

  8 in total
  5 in total

1.  How has the pandemic lockdown changed our daily facial skincare habits?

Authors:  Emilia Ścieszko; Emilian Budny; Helena Rotsztejn; Anna Erkiert-Polguj
Journal:  J Cosmet Dermatol       Date:  2021-03-18       Impact factor: 2.189

2.  Impact of COVID-19 pandemic on dermatology practices: Results of a web-based, global survey.

Authors:  Shashank Bhargava; Charles McKeever; George Kroumpouzos
Journal:  Int J Womens Dermatol       Date:  2020-10-12

Review 3.  The COVID-19 pandemic and its impact on esthetic dermatology.

Authors:  Zeinab Aryanian; Amirhooshang Ehsani; Zahra Razavi; Shahin Hamzelou; Zeinab Mohseni Afshar; Parvaneh Hatami
Journal:  J Cosmet Dermatol       Date:  2022-09-15       Impact factor: 2.189

4.  Effect of the COVID-19 pandemic on the anxiety and depression levels in patients who applied to the cosmetology unit.

Authors:  Selami Aykut Temiz; Koray Durmaz; Recep Dursun; Arzu Ataseven; Begüm Işık; Onur Karaağaç; İlkay Özer; Munise Daye
Journal:  Dermatol Ther       Date:  2020-12-15       Impact factor: 3.858

5.  Impact of COVID-19 pandemic in dermatology outpatient clinics.

Authors:  Rujittika Mungmunpuntipantip; Viroj Wiwanitkit
Journal:  J Cosmet Dermatol       Date:  2021-10-03       Impact factor: 2.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.